CDK Inhibitor

XIE18-6 is a potent INK4C (p18) inhibitor. XIE18-6 shows potent bioactivity in hematopoietic stem cells (HSCs) expansion with an ED₅₀ of 105.5 nM.

AO-365/43472821 is a selective, brain-penetrant Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitor (IC₅₀ = 0.29 μM) and shows a significant inhibitory effect on (CDC-like kinase 1) CLK1 (IC₅₀ = 0.08 μM). AO-365/43472821 could protect the human neuroblastoma cell line SH-SY5Y from Okadaic acid (HY-N6785) (OA)-induced injury. AO-365/43472821 decreased tau (pSer396)/tau and Aβ1-42 protein expression. AO-365/43472821 can be used for the study of Alzheimer's disease.

Abemaciclib (methanesulfonate) (Standard) is the analytical standard of Abemaciclib (methanesulfonate). This product is intended for research and analytical applications. Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective CDK4/6 inhibitor with IC50s of 2 nM and 10 nM for CDK4 and CDK6, respectively.

CDK7-IN-28 (CDK7-1276) is a potent CDK7 inhibitor(IC₅₀＜5 nM). CDK7-IN-28 can inhibit proliferation of MDA-MB-468 cell line by blocking cell cycle and inhibiting DNA replication.

CTX-439 is an orally active, ATP-competitive small-molecule inhibitor of CDK12 and CDK13, with an IC₅₀ of 3.1 nM and a K_d of 0.38 nM against CDK12, and an IC₅₀ of 9.2 nM against CDK13. CTX-439 induces DNA damage and apoptosis in tumor cells. CTX-439 is applicable for the research of breast cancer and ovarian cancer.

CDK12-IN-8 (Compound Cpd143) is an orally active and highly selective inhibitor of cyclin-dependent kinase 12 (CDK12). CDK12-IN-8 inhibits CDK12-mediated phosphorylation of the C-terminal domain (CTD) serine 2 of RNA polymerase II, interfering with gene transcription elongation and DNA damage repair pathways. CDK12-IN-8 is promising for research of cancers with high CDK12 expression such as small cell lung cancer and triple-negative breast cancer.

(S)-JNJ-3738 is a CDK7 inhibitor. (S)-JNJ-3738 regulates kinase activity and exerts weak inhibitory effects on the activity of mutant CDK7. (S)-JNJ-3738 is applicable for cancer research.

Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG) acetate, a CDK2 inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner.

KWZY-11 (Compound 11) is a potent PARP/CDK6 dual inhibitor with IC₅₀ values of 156.8, 197.3, and 13.3 nM for PARP1, PARP2, and CDK6, respectively. KWZY-11 inhibits tumor cell proliferation by regulating the Wnt/β-catenin signaling pathway. KWZY-11 induces excessive DNA damage and apoptosis in MDA-MB-231 breast cancer cells.

CDK16 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK16 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK9-IN-10 is a potent CDK9 inhibitor. CDK9-IN-10 is the ligand for the PROTAC CDK9 degrader-2 (HY-112811).

CDK9-IN-14 is a potent and selective CDK9 inhibitor with IC₅₀ of 6.92 nM. CDK9-IN-14 has a relatively strong inhibitory effect on MV4;11 cells and in vivo tumor models, and has a good selectivity and a low toxicity and few side effects.

(S)-CR8 is the S-isomer of CR8. (S)-CR8 is a potent and selective CDK inhibitor with IC₅₀s of 0.060, 0.080, 0.11, 0.12, and 0.15 μM for CDK2/cyclin E, CDK2/cyclin A, CDK9/cyclin T, CDK5/p25, and CDK1/cyclin B, respectively. (S)-CR8 reduces SH-SY5Y cells survival (IC₅₀ 0.40 μM).

JA397, a chemical probe, is a potent and selective inhibitor for the TAIRE family with cellular activity ranging from IC₅₀ values of 21 nM to 307 nM.

HTH-01-091 TFA is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC₅₀ of 10.5 nM. HTH-01-091 TFA also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK and CLK2. HTH-01-091 TFA can be uesd for breast cancer research.

GW297361 is an oxindole CDK inhibitor that elicits a Pho85-selective response in cells. GW297361 inhibits yeast Cdk1 and Pho85 with IC₅₀s of 20 nM and 400 nM in vitro, respectively.

CDK8-IN-3 is an inhibitor of CDK8 extracted from patent WO2016041618A1, compound example 1.7.

(E/Z)-THZ1 dihydrochloride is a selective inhibitor of CDK7 with an IC₅₀ of 3.2 nM. (E/Z)-THZ1 dihydrochloride has antiproliferative effect.

CDK2 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

2,4,6-Trihydroxybenzoic acid (Standard) is the analytical standard of 2,4,6-Trihydroxybenzoic acid (HY-W077292). This product is intended for research and analytical applications. 2,4,6-Trihydroxybenzoic acid is a CDK inhibitor that dose-dependently inhibits recombinant CDK1, CDK2, and CDK4 with IC₅₀ values of 580, 262, and 403 μM, respectively. 2,4,6-Trihydroxybenzoic acid is also a flavonoid metabolite. Cellular uptake of 2,4,6-Trihydroxybenzoic acid depends on functional SLC5A8. 2,4,6-Trihydroxybenzoic acid can be used in colorectal cancer-related research.